High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 3.4% in the afternoon session after CVS restored Zepbound as a co-preferred option and simultaneously added Lilly's new oral obesity pill Foundayo, making Eli Lilly's full obesity medication portfolio accessible to all three of America's largest pharmacy benefit managers for the first time.
CVS Health Corporation (NYSE:CVS) is one of the 12 Strong Buy Stocks to Buy and Hold for the Next 5 Years. On May 21, 2026, Glenview Capital said CVS Health Corporation (NYSE:CVS) remains one of its three largest positions after a partial rebalance. Glenview said CVS shares have generated a total return of 80% since […]
The change could improve patient access and support future sales growth.
The move gives patients broader access to Lilly's obesity drugs and strengthens competition with Novo Nordisk.
Eli Lilly shares are on pace to hit a new all-time closing high on news of increased insurance coverage for its blockbuster weight-loss drug Zepbound. Lilly shares were recently up 4.4% to $1,130.90. Pharmacy-benefit manager CVS Caremark decided to add back Lilly’s Zepbound weight-loss drug to its lists of preferred drugs.
Investors shouldn't lose sleep over the possibility that the dividend is in danger.
CEO Ariel Katz argues that while AI can replicate workflow SaaS, it can't copy H1’s unique doctor data.
CVS Health will reinstate coverage of Eli Lilly's weight-loss injectable Zepbound and begin coverage of the anti-obesity pill Foundayo.
CVS Health’s decision to expand formulary coverage for key GLP-1 therapies marks a boost for Eli Lilly's obesity drug business.
CVS Health’s Caremark will resume insurance coverage of Eli Lilly’s Zepbound and separately begin covering its Foundayo weight-loss pill.
Eli Lilly and Company (NYSE:LLY) shares gained about 1% in premarket trading Thursday after CVS Caremark announced it would add the company’s obesity treatment Zepbound to its preferred drug formulary. Lilly said the decision means all three of the largest pharmacy benefit managers in the United States will now provide coverage for the company’s full obesity medicine portfolio.
The pharmacy benefit manager dropped Zepbound a year ago in favor of rival Wegovy — now both Lilly and Novo Nordisk drugs will be co-preferred options
The agreement includes Lilly’s new pill Foundayo and restores coverage for Zepbound, erasing what had been a commercial edge for rival Novo Nordisk.
May 28 () - CVS Health said on Thursday it will add Eli Lilly's weight-loss drug Zepbound back to some of its drug lists as an additional preferred option for insurance coverage. Caremark, CVS' pharmacy benefit management unit, had dropped Zepbound from coverage on July 1 last year, while continuing to reimburse for rival Novo Nordisk's Wegovy after negotiating a more favorable price from the Danish drugmaker.
Eva Boratto, who spent more than a decade at CVS in a variety of finance roles, will join the drug distributor later this summer, Cencora announced Wednesday.
The law, which would prohibit PBM conglomerates from owning or operating pharmacies, illegally boots out-of-state companies from Tennessee’s pharmacy market, CVS argued in a suit filed Friday.
The S&P 500 Index ($SPX ) (SPY ) on Tuesday closed up +0.61%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed down -0.23%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +1.76%. June E-mini S&P futures (ESM26 ) rose +0.61%, and June E-mini Nasdaq futures...
The S&P 500 Index ($SPX ) (SPY ) today is up +0.81%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is down -0.10%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +1.74%. June E-mini S&P futures (ESM26 ) are up +0.77%, and June E-mini Nasdaq futures...
CVS Health Corporation (NYSE:CVS) is one of the best medical stocks to invest in according to billionaires. Morgan Stanley lifted the price target on CVS Health Corporation (NYSE:CVS) to $106 from $93 on May 14, maintaining an Overweight rating on the shares. CVS Health Corporation (NYSE:CVS) also received a rating update from Bernstein on May 13, […]
The stocks featured in this article are seeing some big returns. Over the past month, they’ve outpaced the market due to some combination of positive news, upbeat results, or supportive macro developments. As such, investors are taking notice and bidding up shares.
With an annual dividend yield of 2.84%, CVS Health Corporation (NYSE:CVS) is included among the 12 Best Dividend Stocks to Invest in According to Hedge Funds. America’s leading health solutions company, CVS Health Corporation (NYSE:CVS) provides advanced health care from pharmacy services and health plans to health and wellness. On May 20, Mizuho bumped up its price […]
The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant challenges, whether it’s stagnating growth, heavy debt, or disruptive new competitors.
CVS sued Tennessee after Gov. Bill Lee signed legislation to prohibit companies from owning both pharmacy benefit managers and retail pharmacies.
Each stock in this article is trading near its 52-week high. These elevated prices usually indicate some degree of investor confidence, business improvements, or favorable market conditions.
CVS Health Corporation (NYSE:CVS) is included among the 10 High Quality Stocks to Buy According to Hedge Funds. On May 13, Bernstein raised its price recommendation on CVS Health Corporation (NYSE:CVS) to $106 from $94. It reiterated an Outperform rating on the stock. The firm said it still sees CVS as well-positioned to benefit from […]
Hospitals affiliated with Mount Sinai, the University of Michigan and the University of Kansas allege that CVS artificially deflated reimbursement for 340B drugs for years, causing them to lose out on savings.
Three major hospital systems have accused CVS of allegedly diverting hundreds of millions from the federal 340B Drug Pricing Program.
Don’t be surprised if you see more jewelry or hair accessories during your next trip to CVS, Walmart, or Kohl’s.
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
